(Anderson, S.C. – March 10, 2026) – AnMed has become the first health system in the Carolinas to adopt the TriVerity™ test, an innovative decision-support diagnostic designed to help clinicians rapidly assess a patient with suspected infection or sepsis by reading the patient’s immune system.
TriVerity supports timely, confident clinical decisions by helping care teams determine whether the patient has an infection, how sick the patient is, how likely they are to become sicker, and when escalation or de-escalation of treatment may be appropriate.
“Our adoption of this test reflects our commitment to bringing leading‑edge innovation directly to the patients we serve,” said Dr. Brad Mock, AnMed vice president and chief physician executive. “This technology gives our clinical teams clearer, faster insight into a patient’s immune activity and risk of sepsis — allowing us to make more informed decisions and deliver truly personalized care.”
As part of AnMed’s ongoing commitment to innovation and exceptional care, TriVerity supports clinicians in providing timely, effective care to patients with symptoms that may be difficult to distinguish early.
More Confidence When Time Matters
TriVerity provides immune-response information that supports clinical decision-making in cases of suspected acute infection or sepsis, helping clinicians:
- Make faster, more confident decisions when symptoms are nonspecific and time-sensitive
- Improve efficiency by aiding timely triage and care pathway decisions, particularly for high-risk patients
- Advance patient-centered care with earlier diagnostic clarity and more targeted next steps
- Support appropriate level of care decisions by helping guide escalation or de-escalation decisions
“Every hospital should have this test available to save lives,” said Sharon Robb, PhD, AnMed’s supervisor of microbiology and molecular diagnostics. “It will help us to more quickly and efficiently identify patients who don’t necessarily need intervention, those who can go home on antibiotics and those who need to be admitted. It will improve our practices because the results given will drive how each individual patient is treated.
“Innovations like TriVerity reflect our commitment to bringing advanced technologies to our community. Being first in the Carolinas underscores our focus on exceptional, leading-edge care close to home.”
The TriVerity adoption comes just weeks after Dr. Brian Miller and AnMed Arrhythmia became one of the first in the nation make the FARAPOINT Pulsed Field Ablation Catheter from Boston Scientific available to patients. That technology represents significant progress in treating people with right atrial flutter, a growing public health challenge.
About TriVerity™
TriVerity™ is a rapid blood test designed to support clinical decision-making in patients with suspected infection or sepsis. By measuring the expression of immune system mRNAs and applying advanced algorithms, TriVerity provides clinicians with objective insight into a patient’s immune system in ~30 minutes. The test helps clinicians assess the likelihood and severity of infection and guide timely patient disposition and treatment decisions.
About Inflammatix
Inflammatix is a Sunnyvale, California-based molecular diagnostics company that is redefining emergency and critical care medicine by translating a patient’s immune system response into real-time decision support that improves patient outcomes and hospital operations. Their lead product, the TriVerity™ test, runs on the Myrna™ instrument to identify bacterial/viral infections and illness severity.
